AUROBINDO PHARMA
|
The Current P/E Ratio of AUROBINDO PHARMA is 19.75.
| Share Price | ₹1,172.3 | Jan 16,2026 |
| Market Cap | ₹68,087.2 Cr | |
| Earnings-TTM | ₹3,447.8 Cr | TTM-Consolidated Results |
| Price/Earnings | 19.75x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of AUROBINDO PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹68,087.2 Cr] as on Jan 16,2026
(/) Earnings [ ₹3,447.8 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 19.75x ]
Thus, for AUROBINDO PHARMA , the investors are currently willing to pay 19.75 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of AUROBINDO PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of AUROBINDO PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of AUROBINDO PHARMA
PE Ratio Performance Analysis for AUROBINDO PHARMA
- AUROBINDO PHARMA 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 15.93x.
- AUROBINDO PHARMA 's operated at median p/e ratio of 15.75x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, AUROBINDO PHARMA 's p/e ratio peaked in Mar2024 at 20.12x.
- AUROBINDO PHARMA 's p/e ratio hit its five-year low in Mar2021 of 9.68x.
How does AUROBINDO PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| AUROBINDO PHARMA | 3,447.75 | 19.75 | 68,087.2 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,517.90 | 38.08 | 400,497.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 66.60 | 165,492.0 |
| CIPLA LTD | 5,453.86 | 20.70 | 112,922.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 63.56 | 136,013.0 |
| DR REDDYS LABORATORIES LTD | 5,721.40 | 17.15 | 98,115.0 |
| MANKIND PHARMA LTD | 1,767.06 | 50.84 | 89,832.6 |
| ZYDUS LIFESCIENCES LTD | 4,973.40 | 17.56 | 87,321.0 |
| LUPIN LTD | 4,347.53 | 22.87 | 99,410.8 |
| ABBOTT INDIA LTD | 1,508.95 | 39.12 | 59,024.1 |
| ALKEM LABORATORIES LTD | 2,411.72 | 28.93 | 69,768.6 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs AUROBINDO PHARMA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 17.15x |
| Max industry PE | 66.60x |
| Median industry PE | 28.93x |
| Average industry PE | 35.01x |
You may also like the below Video Courses